This summer has been busy for Verantos, engaging global audiences on high-validity real-world evidence (RWE). We presented to an active crowd at BIO’s International Convention. Our ground-breaking work in migraine was presented at the American Headache Society’s Annual Scientific Meeting. We chaired a panel at DIA’s global meeting. The FDA highlighted our demonstration project at the NIH Pragmatic Trials Collaboratory.
Company News
Follow us on LinkedIn to stay up-to-date on the latest Verantos and high-validity real-world evidence news.
Verantos presents at BIO
Verantos presented an overview of the TRUST FDA demonstration project in this panel at BIO’s 2022 International Convention. Joined by Genentech, Verantos shared its model of accuracy, completeness, and traceability, which is increasingly becoming the standard in data quality.
Verantos enables high-validity RWE in migraine
Lundbeck, a Verantos customer, presented a poster on migraine phenotyping at the American Headache Society’s 64th Annual Scientific Meeting. The approach leverages advanced data and technologies. The model achieves significant results for key migraine characteristics such as headache severity and associated symptoms.